EMA Reviewing Guide To Support New Genome Editing Technologies, CAR-T Cell Therapies
The European Medicines Agency is updating its five-year old guideline on drugs containing genetically modified cells to factor in rapid scientific developments in relation to gene editing technologies, and the development of promising new cancer immunotherapies, such as CAR-T cells.
You may also be interested in...
The 2020 work plan of the European Medicines Agency’s Committee on Advanced Therapies includes initiatives to support the implementation of the EU regulations on medical devices and IVDs.
The 2020 work plan of the European Medicines Agency’s committee on advanced therapies shows that two keenly-awaited guidelines are due to be finalized this year.
The European Medicines Agency's current thinking on the clinical development of CAR-T cells is outlined in a new annex.